Chapter 4 140 Wolf, N. I., Vanderver, A., van Spaendonk, R. M., Schiffmann, R., Brais, B., Bugiani, M., Sistermans, E., Catsman-Berrevoets, C., Kros, J. M., Pinto, P. S., Pohl, D., Tirupathi, S., Stromme, P., de Grauw, T., Fribourg, S., Demos, M., Pizzino, A., Naidu, S., Guerrero, K., . . . Bernard, G. (2014). Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. Neurology, 83(21), 1898-1905. https://doi.org/10.1212/WNL.0000000000001002 Yi, J., Chen, B., Yao, X., Lei, Y., Ou, F., & Huang, F. (2019). Upregulation of the lncRNA MEG3 improves cognitive impairment, alleviates neuronal damage, and inhibits activation of astrocytes in hippocampus tissues in Alzheimer's disease through inactivating the PI3K/Akt signaling pathway. J Cell Biochem, 120(10), 18053-18065. https://doi.org/10.1002/jcb.29108 Zhang, H., Tao, J., Zhang, S., & Lv, X. (2020). LncRNA MEG3 Reduces Hippocampal Neuron Apoptosis via the PI3K/AKT/mTOR Pathway in a Rat Model of Temporal Lobe Epilepsy. Neuropsychiatr Dis Treat, 16, 2519-2528. https://doi.org/10.2147/NDT.S270614 Zhang, X., Zhou, Y., Mehta, K. R., Danila, D. C., Scolavino, S., Johnson, S. R., & Klibanski, A. (2003). A pituitaryderived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab, 88(11), 5119-5126. https://doi.org/10.1210/jc.2003-030222 Zhang, Y., Liu, C. Y., Chen, W. C., Shi, Y. C., Wang, C. M., Lin, S., & He, H. F. (2021). Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review. Cell Biosci, 11(1), 151. https://doi.org/10.1186/s13578-021-00657-7 Zhou, Y., Song, H., & Ming, G. L. (2024). Genetics of human brain development. Nat Rev Genet, 25(1), 26-45. https://doi.org/10.1038/s41576-023-00626-5
RkJQdWJsaXNoZXIy MTk4NDMw